Document is current
Any future updates will be listed below
-
Authors
Toulmonde, Maud
Guégan, Jean-Philippe
Spalato-Ceruso, Mariella https://orcid.org/0000-0002-7582-3365
Valentin, Thibaud
Bahleda, Rastilav
Peyraud, Florent
Rey, Christophe
Kind, Michèle
Cantarel, Coralie
Bellera, Carine
Vanhersecke, Lucile https://orcid.org/0000-0001-7733-7806
Bessede, Alban
Italiano, Antoine https://orcid.org/0000-0002-8540-5351
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (RHU CONDOR, RHU CONDOR)
- License Information
-
More Information
Article History
Received: 1 August 2024
Revised: 5 February 2025
Accepted: 22 May 2025
First Online: 27 June 2025
Competing interests
: A.I.: research grant (AstraZeneca, Bayer, BMS, Merck, MSD, Pharmamar). J.P.G., C.R., and A.B.: employees of Explicyte. The other co-authors have nothing to disclose. The other authors declare that they have no competing interests.
: This study was approved by the Comité de Protection des Personnes (CPP) Sud-Ouest et Outre Mer III (Bordeaux, France) according to good clinical practices and applicable laws and regulations. All methods were performed in accordance with the relevant guidelines and regulations. All patients provided written informed consent.
